Recent News & Events
 

About

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Broomfield, Colorado.

Annual Shareholder Meeting Information:

When: May 21st, 2010 at 9:00 am MDT

Where: Renaissance Suites, 500 Flatiron Blvd., Broomfield, CO 80021

For directions to the Renaissance Suites, please click here.

To view and print ARCA biopharma, Inc.'s Annual Report on Form 10-K, please click here.

To view and print ARCA biopharma, Inc.'s Proxy Statement, please click here.

To view and print ARCA biopharma, Inc.'s Stockholder Meeting Notice, please click here.

 

Science

ARCA is currently developing Gencaro™ (tradename pending FDA approval) (bucindolol hydrochloride) for the treatment of chronic heart failure. Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator. Gencaro™ is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro™ is well-tolerated in patients with advanced HF. ARCA has identified common genetic variations, or genetic markers, that it believes predict patient response to Gencaro™.

 
           
ARCA ©2010 ARCA biopharma | Home | Site Map | Legal Disclaimer